Athena Athena

X
[{"orgOrder":0,"company":"Neurimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Ethris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurimmune and Ethris Enter Collaboration to Rapidly Develop Inhaled mRNA-based Antibody Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approval of Aducanumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ono Expands Drug Discovery Collaboration with Neurimmune AG in the Field of Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$760.0 million","upfrontCash":"$30.0 million","newsHeadline":"AstraZeneca and Neurimmune Close Exclusive Global Collaboration and Licence Agreement to Develop and Commercialise NI006","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$760.0 million","upfrontCash":"$30.0 million","newsHeadline":"AstraZeneca and Neurimmune Sign Exclusive Global Collaboration and Licence Agreement to Develop and Commercialise NI006","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurimmune to Regain Global Rights to Brain Amyloid Depleter for the Treatment of Alzheimer\u2019s disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Neurimmune

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the termination, Neurimmune regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid, for the treatment and prevention of Alzheimer’s disease.

            Lead Product(s): Aducanumab

            Therapeutic Area: Neurology Product Name: BIIB037

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: $380.0 million Upfront Cash: Undisclosed

            Deal Type: Termination January 31, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NI006 adds a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies focused on amyloidosis and strengthens the Company’s broader commitment to addressing cardiomyopathies that can lead to heart failure (HF).

            Lead Product(s): NI006

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: NI006

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Alexion Pharmaceuticals

            Deal Size: $760.0 million Upfront Cash: $30.0 million

            Deal Type: Collaboration March 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In the new collaboration, companies aim to generate and validate human-derived monoclonal antibodies (NI504) against Ono’s selected drug targets. Ono will obtain exclusive rights for worldwide development and commercialization of antibody products resulting from collaboration.

            Lead Product(s): Human-derived Monoclonal Antibodies

            Therapeutic Area: Neurology Product Name: NI504

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ono Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Alexion will be granted an exclusive worldwide licence to develop, manufacture and commercialise NI006. NI006, an ATTR depleter, a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies focused on amyloidosis.

            Lead Product(s): NI006

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: NI006

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Alexion Pharmaceuticals

            Deal Size: $760.0 million Upfront Cash: $30.0 million

            Deal Type: Collaboration January 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The data of three separate clinical studies unequivocally show that aducanumab’s biological activity removed amyloid from brains of patients with Alzheimer’s disease.

            Lead Product(s): Aducanumab

            Therapeutic Area: Neurology Product Name: Aduhelm

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration.

            Lead Product(s): NI007

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Recipient: Ethris

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 01, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy of NI006 in patients with wild-type and hereditary forms of ATTR cardiomyopathy.

            Lead Product(s): NI006

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY